Privately-held biotech Enteris BioPharma has granted to Cara Therapeutics (Nasdaq: CARA) a non-exclusive, royalty-bearing license to Peptelligence technology to develop, manufacture and commercialize oral Korsuva (CR845/difelikefalin) worldwide, excluding Japan and South Korea.
Peptelligence is Enteris' proprietary platform for the oral delivery of peptides and BCS class II, III and IV small molecules, while Oral Korsuva is currently the subject of three separate Phase II clinical trials for pruritis in patients with hepatic impairment due to primary biliary cholangitis, stage III-V chronic kidney disease, and atopic dermatitis.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze